Observational studyBMC infectious diseases2025
Serum levels of Interleukin-10, Interleukin-6, and leptin in patients with Mycobacterium leprae-Helminth Co-Infections.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLeprosy remains a public health problem in several countries, including Indonesia, due to its surrounding disability, stigma, and discrimination. In leprosy, compromised immune responses frequently affect the occurrence of helminth infections, which are known to contribute to a number of diseases by upregulating T-helper 2. Elevated levels of interleukin (IL)-10, IL-6, and leptin have been associated with helminth infection and leprosy, respectively. PURPOSES: This study aimed to measure the serum levels of IL-10, IL-6, and leptin in leprosy patients with and without helminth co-infections. PATIENTS AND
methodsA cross-sectional design was used for this observational clinical study. A total of 32 leprosy patients who fulfilled our inclusion and exclusion criteria were recruited. The quantification of IL-10 and IL-6 levels was performed using serum samples with a quantitative sandwich enzyme-linked immunosorbent assay method. Additionally, the quantification of leptin serum was also carried out. The helminth's eggs were examined using the Kato-Katz technique.
resultsThis study revealed that helminth co-infection was present in five out of 32 (15.6%) leprosy patients. The types of helminth found in leprosy patients with helminth infections were Ascaris lumbricoides and Trichuris trichiura, with a mild intensity of infection. For leprosy with helminth infection, the mean IL-10, IL-6, and leptin serum levels were 86.43 pg/ml ± 4.34 pg/ml, 447.42 pg/ml ± 122.15 pg/ml, and 19,272.85 pg/ml ± 4,065.23 pg/ml, respectively. Meanwhile, the mean IL-10, IL-6, and leptin serum levels for leprosy without helminth infection were 72.97 pg/ml ± 14.69 pg/ml, 161.77 pg/ml ± 63.98 pg/ml, and 14,649.07 pg/ml ± 2,002.66 pg/ml, respectively. Based on an independent t-test, the difference in serum levels of IL-10 and IL-6 in leprosy patients with and without helminth infections was p = 0.001 and p = 0.0001, respectively. However, based on the Mann-Whitney test, the serum level of leptin between leprosy patients with and without helminth infections was p = 0.062.
conclusionThe proportion of helminth infection in leprosy patients is 15.6%. Leprosy patients with helminth infections have considerably greater serum levels of IL-10 and IL-6, suggesting that helminth infection influences leprosy patients' immunological responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.